UBC and CDRD spinout Sitka Biopharma has now lured $5.5m in total and is readying its bladder cancer treatment for initial clinical trials.

Complion collected funding from investors including the multi-university-backed Ohio Innovation Fund for its regulatory compliance software platform catered to sites conducting clinical research.

Regenerative craniofacial implant manufacturer OssDsign has amassed $19.7m altogether as it prepares to take its products based on Karolinska and Uppsala university research into new markets.

The gains came against a backdrop of falling net profits and cash reserves that will test Karolinska Development as it looks ahead to convertible debt obligations.

Legend Capital led a $29.5m round for SciWind, which is developing treatments for metabolic and liver diseases, with backing from Kawin Technology.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Axovant Sciences has spun out its small molecule team into a startup called Arvelle, which will develop an anti-epileptic drug after raising more than $100m in external funding.

Lilly Asia Ventures had contributed to cancer diagnostics technology provider Burning Rock's series C round, which was led by GIC.

Novartis and Johnson & Johnson have contributed to a series A round for Vor Biopharma, an oncology drug developer co-founded by PureTech Health.

Samsung Next and GreatPoint Ventures supplied series A capital for emergency response software provider RapidDeploy, which recently moved from South Africa to the US.